State Ledger
Company profile

Alzamend Neuro, Inc. CIK 1677077

Ticker
ALZN (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Atlanta, GA 30326
Fiscal year end
2026 (FY)
Market Data
Close
$1.36
Change
+$0.14
Change %
11.48%
Volume
101

ALZN · trading date Oct 9, 2026 · previous close $1.22 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$8.77M
Total assets
$2.08M
Total liabilities
$1.35M
Stockholders' equity
$733.2K
Cash & equivalents
$710.7K
Operating income
-$8.77M
Operating cash flow
-$8.07M
Capital expenditures
—

Fiscal year 2026, via 10-K filed 2026-07-22. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
64.7%
Equity / assets
35.3%
CapEx / revenue
—
Operating cash flow / net income
0.92×

Derived from the fiscal year 2026 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2026 — -$8.77M $2.08M $1.35M $733.2K
2025 — -$4.51M $4.60M $634.8K $3.97M
2024 — -$9.95M $631.6K $3.23M -$2.59M
2023 — -$14.88M $5.92M $2.87M $3.05M
2022 — -$12.36M $14.52M $1.16M $13.35M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-09-10
Financials filed via
Form 10-K
filed 2026-07-22

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Atlanta, GA 30326
480 PEACHTREE ROAD NE, SECOND FLOOR
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:28 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Georgia — Public Companies